Increase in prevalence of genetic disorders, shift towards personalized medicine, and surge in demand for forensic DNA analysis are the major factors which drive the global genotyping market growth.
WILMINGTON, Del., Feb. 16, 2026 /PRNewswire/ — Allied Market Research published a report, titled, “Genotyping Market by Product (Instruments, Reagents and Kits and Software and Services), Technology (PCR, Capillary Electrophoresis, Microarrays, Sequencing, Mass Spectrometry, and Others), Application (Pharmacogenomics, Diagnostics and Personalized Medicine, Agricultural Biotechnology, Animal Genetics and Others), and End User (Pharmaceutical and Biopharmaceutical Companies, Diagnostics and Research Laboratories, and Others): Global Opportunity Analysis and Industry Forecast, 2024-2033″. According to the report, the genotyping market was valued at $16.8 billion in 2023, and is estimated to reach $61.6 billion by 2033, growing at a CAGR of 13.8% from 2024 to 2033.
Prime determinants of growth
The surge in prevalence of genetic disorders worldwide, such as cancer, cardiovascular diseases, and neurological disorders, shift towards personalized medicine, and increase in demand for forensic DNA analysis are the major factors that drive the growth of the genotyping market. However, the high cost of genotyping technologies restricts market growth. Moreover, advancements in genomic research offers remunerative opportunities for the expansion of the global genotyping market.
Request Sample of the Report on Global Genotyping Market 2033 – https://www.alliedmarketresearch.com/request-sample/840
Report coverage & details
In research and population genomics, scientists use genotyping to study genetic associations with disease susceptibility, behavioral traits, and evolutionary patterns. These insights help drive preventive public health strategies and research efforts aimed at understanding disease mechanisms.
Genotyping also extends beyond human health. In agriculture and animal breeding, genotyping identifies desirable traits in crops and livestock. Plant breeders use genotyping to select for disease resistance, higher yield, and tolerance to environmental stress. Similarly, livestock genotyping supports traits such as growth rate, fertility, and product quality. These applications enhance productivity, sustainability, and food security.
Want to Explore More, Connect to our Analyst – https://www.alliedmarketresearch.com/connect-to-analyst/840
Segment Highlights
The reagents and kits segment dominated the market share in 2023
By product, the reagents and kits segment dominated the market share in 2023. This is attributed to increase in adoption of genotyping technologies across research, diagnostics, agriculture, and forensic science. In addition, advancements in genotyping platforms and techniques require specialized reagents and kits tailored to specific applications. This enhances the growth of the genotyping market.
The diagnostics and personalized medicine segment dominated the market share in 2023
By application, the diagnostics and personalized medicine segment dominated the market share in 2023. This is attributed to increase in demand for genetic testing and tailored treatment approaches and the shift towards personalized medicine. In addition, the rise in prevalence of genetic disorders and the surge in emphasis on preventive healthcare contribute to the growth of the segment. The diagnostics and personalized medicine segment is expected to experience growth with ongoing technological advancements and expanding applications in healthcare.
The diagnostics and research laboratories segment dominated the market share in 2023
By end user, the diagnostics and research laboratories segment dominated the market share in 2023. This is attributed to increase in demand for genotyping assays in clinical diagnostics, disease screening, and personalized medicine. Research laboratories continue to drive innovation in genomics research, drug discovery, and agricultural biotechnology, contributing to the expansion of the genotyping market. In addition, advancements in genotyping technologies and bioinformatics tools enhance the capabilities of diagnostics and research laboratories to analyze genetic data accurately and efficiently thereby propelling the segment growth.
For Purchase Related Queries/Inquiry – https://www.alliedmarketresearch.com/purchase-enquiry/840
North America to maintain its dominance by 2033
North America is poised to maintain its leadership status in the genotyping market during the forecast period owing to robust investments in research and development, advanced healthcare infrastructure, and a strong regulatory framework supporting genetic technologies. The presence of major market players and academic institutions further fosters the growth of the market in North America.
Key Players
David Correa
1209 Orange Street,
Corporation Trust Center,
Wilmington, New Castle,
Delaware 19801 USA.
Toll Free: +1-800-792-5285
Int’l: +1-503-894-6022
UK: +44-845-528-1300
Hong Kong: +852-301-84916
India (Pune): +91-20-66346060
Fax: +1-855-550-5975
[email protected]
Web: https://www.alliedmarketresearch.com Logo: https://mma.prnewswire.com/media/636519/Allied_Market_Research_Logo.jpg SOURCE Allied Market Research
|
Report Coverage |
Details |
|
Forecast Period |
2024–2033 |
|
Base Year |
2023 |
|
Market Size in 2023 |
$16.8 billion |
|
Market Size in 2033 |
$61.6 billion |
|
CAGR |
13.8 % |
|
No. of Pages in Report |
231 |
|
Segments Covered |
Product, Technology, Application, End User, and Region. |
|
Drivers |
Increasing prevalence of genetic disorders |
|
Shift towards personalized medicine |
|
|
Increasing demand for forensic DNA analysis |
|
|
Opportunity |
Advancements in genomic research |
|
Restraint |
High cost of genotyping technologies |
- Illumina Inc.
- Thermo Fisher Scientific Inc.
- QIAGEN
- F. Hoffmann-La Roche Ltd
- Danaher Corporation
- Agilent Technologies Inc
- Eurofins Genomics LLC
- Bio-Rad Laboratories Inc.
- PacBio
- Integrated DNA Technologies Inc.
- In July 2023, QIAGEN announced the launch of the QIAseq Normalizer Kits that give researchers a fast, convenient and cost-effective method to pool different DNA libraries for best-quality results from next-generation sequencing (NGS) runs.
- In June 2022, Roche announced the launch of a human papillomavirus (HPV) self-sampling solution in countries accepting the CE mark. This new solution enables a patient to privately collect her sample for HPV screening while at a healthcare facility, following instructions provided by a healthcare worker. The clinically-validated vaginal sample is analyzed with the Roche cobas HPV test on a Roche molecular instrument.
David Correa
1209 Orange Street,
Corporation Trust Center,
Wilmington, New Castle,
Delaware 19801 USA.
Toll Free: +1-800-792-5285
Int’l: +1-503-894-6022
UK: +44-845-528-1300
Hong Kong: +852-301-84916
India (Pune): +91-20-66346060
Fax: +1-855-550-5975
[email protected]
Web: https://www.alliedmarketresearch.com Logo: https://mma.prnewswire.com/media/636519/Allied_Market_Research_Logo.jpg SOURCE Allied Market Research

Source link
















Leave a Reply